eCite Digital Repository

Enhanced anti-amyloid effect of combined leptin and pioglitazone in app/ps1 transgenic mice

Citation

Liu, Y and Hanson, KA and McCormack, G and Atkinson, RAK and Dittmann, J and Vickers, JC and Fernandez-Martos, CM and King, AE, Enhanced anti-amyloid effect of combined leptin and pioglitazone in app/ps1 transgenic mice, Current Alzheimer Research, 17, (14) pp. 1294-1301. ISSN 1567-2050 (2020) [Refereed Article]

PDF
Pending copyright assessment - Request a copy
3Mb
  

DOI: doi:10.2174/1567205018666210218163857

Abstract

Background: Alzheimer's disease (AD) has challenged single-target therapeutic strategies, raising the possibility that combined therapies may offer a more effective treatment strategy.

Objective:There is substantial evidence for the efficacy of leptin (L) (neuroprotective hormone) and pioglitazone (P) (anti-inflammatory agent) as monotherapies in AD. We have previously shown that combination treatment of L+P in APP/PS1 mice at the onset of pathology significantly improved memory and reduced brain Aβ levels relative to control mice. In this new study, we sought to replicate our previous findings in a new cohort of APP/PS1 mice to further confirm whether the combined treatment of L+P is superior to each treatment individually.

Methods: We have re-evaluated the effects of L+P co-treatment in APP/PS1 mice using thioflavin-S staining, MOAβ immunolabeling, and enzyme-linked immunosorbent assay (ELISA) to examine effects on Aβ levels and pathology, relative to animals that received L or P individually.

Results: We demonstrated that a combination of L and P significantly enhances the anti-Aβ effect of L or P in the hippocampus of APP/PS1 mice.

Conclusion: Our findings suggest that combining L and P significantly enhances the anti-Aβ effect of L or P in the hippocampus of APP/PS1 mice and maybe a potential new effective strategy for AD therapy.

Item Details

Item Type:Refereed Article
Keywords:APP/PS1 transgenic mouse, Alzheimer's disease (AD), dementia, leptin, pioglitazone, signaling pathways
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Clinical chemistry (incl. diagnostics)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Diagnosis of human diseases and conditions
UTAS Author:Liu, Y (Dr Yao Liu)
UTAS Author:McCormack, G (Mr Graeme McCormack)
UTAS Author:Atkinson, RAK (Dr Rachel Atkinson)
UTAS Author:Dittmann, J (Mr Justin Dittmann)
UTAS Author:Vickers, JC (Professor James Vickers)
UTAS Author:King, AE (Professor Anna King)
ID Code:152774
Year Published:2020
Web of Science® Times Cited:3
Deposited By:Medicine
Deposited On:2022-08-24
Last Modified:2022-08-24
Downloads:0

Repository Staff Only: item control page